Drug Manufacturers - Specialty & Generic
Compare Stocks
2 / 10Stock Comparison
SHPH vs AGEN
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
SHPH vs AGEN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $4M | $132M |
| Revenue (TTM) | $0.00 | $114M |
| Net Income (TTM) | $-11M | $115K |
| Gross Margin | — | 35.7% |
| Operating Margin | — | -17.7% |
| Forward P/E | — | 1.8x |
| Total Debt | $1M | $10M |
| Cash & Equiv. | $2M | $3M |
SHPH vs AGEN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 22 | May 26 | Return |
|---|---|---|---|
| Shuttle Pharmaceuti… (SHPH) | 100 | 0.0 | -100.0% |
| Agenus Inc. (AGEN) | 100 | 6.9 | -93.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SHPH vs AGEN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SHPH is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.24
- Lower volatility, beta 1.24, current ratio 1.44x
- Beta 1.24, current ratio 1.44x
AGEN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 10.4%, EPS growth 100.0%, 3Y rev CAGR 5.2%
- -94.3% 10Y total return vs SHPH's -100.0%
- 10.4% revenue growth vs SHPH's -16.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.4% revenue growth vs SHPH's -16.6% | |
| Quality / Margins | 0.1% margin vs SHPH's -52.7% | |
| Stability / Safety | Beta 1.24 vs AGEN's 2.72 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +27.1% vs SHPH's -89.1% | |
| Efficiency (ROA) | 0.1% ROA vs SHPH's -253.9% |
SHPH vs AGEN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SHPH vs AGEN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
AGEN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
AGEN and SHPH operate at a comparable scale, with $114M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $114M |
| EBITDAEarnings before interest/tax | -$11M | -$10M |
| Net IncomeAfter-tax profit | -$11M | $115,000 |
| Free Cash FlowCash after capex | -$11M | -$159M |
| Gross MarginGross profit ÷ Revenue | — | +35.7% |
| Operating MarginEBIT ÷ Revenue | — | -17.7% |
| Net MarginNet income ÷ Revenue | — | +0.1% |
| FCF MarginFCF ÷ Revenue | — | -139.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +27.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -183.8% | +85.3% |
Valuation Metrics
AGEN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $4M | $132M |
| Enterprise ValueMkt cap + debt − cash | $3M | $140M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -1102.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 1.79x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 1.16x |
| Price / BookPrice ÷ Book value/share | 10.28x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
AGEN leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), AGEN scores 6/9 vs SHPH's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -4.8% | — |
| ROA (TTM)Return on assets | -2.5% | +0.1% |
| ROICReturn on invested capital | -4.6% | — |
| ROCEReturn on capital employed | -2.6% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | 1.65x | — |
| Net DebtTotal debt minus cash | -$746,672 | $7M |
| Cash & Equiv.Liquid assets | $2M | $3M |
| Total DebtShort + long-term debt | $1M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -50.60x | 1.11x |
Total Returns (Dividends Reinvested)
AGEN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AGEN five years ago would be worth $611 today (with dividends reinvested), compared to $1 for SHPH. Over the past 12 months, AGEN leads with a +27.1% total return vs SHPH's -89.1%. The 3-year compound annual growth rate (CAGR) favors AGEN at -51.0% vs SHPH's -86.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -61.0% | +16.1% |
| 1-Year ReturnPast 12 months | -89.1% | +27.1% |
| 3-Year ReturnCumulative with dividends | -99.7% | -88.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -93.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -94.3% |
| CAGR (3Y)Annualised 3-year return | -86.0% | -51.0% |
Risk & Volatility
Evenly matched — SHPH and AGEN each lead in 1 of 2 comparable metrics.
Risk & Volatility
SHPH is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGEN currently trades 51.1% from its 52-week high vs SHPH's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 2.72x |
| 52-Week HighHighest price in past year | $11.25 | $7.34 |
| 52-Week LowLowest price in past year | $0.50 | $2.71 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +51.1% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 48.8 |
| Avg Volume (50D)Average daily shares traded | 840K | 814K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $7.33 |
| # AnalystsCovering analysts | — | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
AGEN leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
SHPH vs AGEN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SHPH or AGEN a better buy right now?
Analysts rate Agenus Inc.
(AGEN) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SHPH or AGEN?
Over the past 5 years, Agenus Inc.
(AGEN) delivered a total return of -93. 9%, compared to -100. 0% for Shuttle Pharmaceuticals Holdings, Inc. (SHPH). Over 10 years, the gap is even starker: AGEN returned -94. 3% versus SHPH's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SHPH or AGEN?
By beta (market sensitivity over 5 years), Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the lower-risk stock at 1. 24β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 120% more volatile than SHPH relative to the S&P 500.
04Which is growing faster — SHPH or AGEN?
On earnings-per-share growth, the picture is similar: Agenus Inc.
grew EPS 100. 0% year-over-year, compared to -2159. 3% for Shuttle Pharmaceuticals Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SHPH or AGEN?
Agenus Inc.
(AGEN) is the more profitable company, earning 0. 1% net margin versus 0. 0% for Shuttle Pharmaceuticals Holdings, Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHPH leads at 0. 0% versus -18. 0% for AGEN. At the gross margin level — before operating expenses — AGEN leads at 90. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — SHPH or AGEN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SHPH or AGEN better for a retirement portfolio?
For long-horizon retirement investors, Shuttle Pharmaceuticals Holdings, Inc.
(SHPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 24)). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SHPH: -100. 0%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SHPH and AGEN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.